Emcure Pharmaceuticals (EMCURE) Fundamentals 2026 — P/E 38.7x, Revenue Analysis | SniperIQ
Emcure Pharmaceuticals (EMCURE) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹35,834 Crore, trading at ₹1889.20 on the NSE. This SniperIQ fundamentals page covers Emcure Pharmaceuticals's valuation (P/E 38.7x, P/B 7.2x), profitability (net margin 10.0%), revenue (₹9,204 Crore in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Emcure Pharmaceuticals's market cap?
Emcure Pharmaceuticals (EMCURE) has a market capitalization of approximately ₹35,834 Crore, trading at ₹1889.20 on the NSE. Market cap moves with the live share price.
What is Emcure Pharmaceuticals's P/E ratio?
Emcure Pharmaceuticals's trailing twelve-month P/E ratio is 38.7x, with a price-to-book (P/B) of 7.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Emcure Pharmaceuticals?
Emcure Pharmaceuticals runs a net profit margin of 10.0%, a gross margin of 38.9%, and an operating margin of 14.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Emcure Pharmaceuticals generate?
Emcure Pharmaceuticals reported revenue of ₹9,204 Crore for fiscal year 2025, with net income of ₹924 Crore and earnings per share (EPS) of 48.77. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Emcure Pharmaceuticals pay a dividend?
Emcure Pharmaceuticals offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Emcure Pharmaceuticals financially healthy?
Emcure Pharmaceuticals carries a debt-to-equity ratio of 0.31x and a current ratio of 1.43x, with a market beta of -0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Emcure Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Emcure Pharmaceuticals (EMCURE) the key facts are: market cap ₹35,834 Crore, P/E 38.7x, revenue ₹9,204 Crore, 52-week range 1260-1944. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Emcure Pharmaceuticals's full fundamentals live
Get Emcure Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.